Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 172 clinical trials
featured
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.

renal angiogram
antihypertensive therapy
antihypertensive drugs
angiography
hypertensive medication
University Clinic Erlangen
 (8.7 away) Contact site
  • 877 views
  • 13 Jun, 2021
  • +82 other locations
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Research Site
 (8.7 away) Contact site
  • 147 views
  • 03 Jun, 2021
  • +262 other locations
Re-evaluation of Optimal Re-synchronisation Therapy in Patients With Chronic Heart Failure

The objective of the study is to demonstrate that in patients with chronic heart failure who receive optimal medical treatment for this condition and have indication for Cardiac Resynchronisation Therapy, the implantation of a pacemaker (index group) is not inferior to defibrillator (control group) with respect to all-cause mortality.

cardiac resynchronization therapy
medical therapy
ejection fraction
cardiomyopathy
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 2 views
  • 16 Jun, 2021
  • +349 other locations
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Novartis Investigative Site
 (8.7 away) Contact site
  • 211 views
  • 02 Jun, 2021
  • +361 other locations
A Study to Test the Pharmacokinetics Efficacy and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures

The purpose of the study is to evaluate the pharmacokinetics (PK) of brivaracetam (BRV) in neonates who have seizures that are not adequately controlled with previous antiepileptic drug (AED) treatment, and to identify the optimal BRV dose (Exploratory Cohort) for the treatment of subjects enrolled into the Confirmatory Cohorts of …

N01349 218
 (9.4 away) Contact site
  • 1 views
  • 14 Mar, 2021
  • +15 other locations
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-[L]1) agent …

adjuvant chemotherapy
vinflunine
pembrolizumab
docetaxel
transitional cell carcinoma
Friedrich-Alexander Universitaet Urologische Universitaetskl
 (8.7 away) Contact site
  • 271 views
  • 03 Jun, 2021
  • +587 other locations
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with …

University Clinic Erlanger
 (8.7 away) Contact site
  • 2 views
  • 05 Jun, 2021
  • +77 other locations
A Study to Determine the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Universitaetsklinikum Erlangen /ID# 214196
 (8.7 away) Contact site
  • 22 views
  • 27 Jan, 2021
  • +41 other locations
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptimal response may benefit from switching to risankizumab with regard to skin symptoms, quality of life symptoms and psoriasis symptoms. …

secukinumab
ixekizumab
Universitaetsklinikum Erlangen /ID# 214228
 (8.7 away) Contact site
  • 49 views
  • 16 Jun, 2021
  • +74 other locations
Efficacy Safety and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. …

apremilast
Research site
 (8.7 away) Contact site
  • 265 views
  • 14 Jun, 2021
  • +267 other locations